Gemigliptin added to ongoing metformin therapy provides sustained glycaemic control over 52 weeks and was well tolerated in patients with type 2 diabetes

被引：0

作者：

Rhee, E. J. ^{[1
]}

Min, K. W. ^{[2
]}

Jang, H. C. ^{[3
]}

Chung, C. H. ^{[4
]}

Nam-Goong, I. S. ^{[5
]}

Bae, H. Y. ^{[6
]}

Baik, S. H. ^{[7
]}

Shivane, V. K. ^{[8
]}

Sosale, A. R. ^{[9
]}

Dharmalingam, M. ^{[10
]}

Gandhi, P. ^{[11
]}

Gupta, S. K. ^{[12
]}

Ahn, J. Y. ^{[13
]}

Bang, K. S. ^{[13
]}

Lee, M. K. ^{[14
]}

机构：

[1] Kangbuk Samsung Med Ctr, Seoul, South Korea

[2] Eulji Univ, Sch Med, Seoul, South Korea

[3] Seoul Natl Univ, Bundang Hosp, Songnam, South Korea

[4] Wonju Christian Hosp, Wonju, South Korea

[5] Ulsan Univ Hosp, Ulsan, South Korea

[6] Chosun Univ Hosp, Kwangju, South Korea

[7] Korea Univ, Guro Hosp, Seoul, South Korea

[8] Shivane, Mumbai, Maharashtra, India

[9] Diacon Hosp, Diabet Care & Res Ctr, Bangalore, Karnataka, India

[10] Bangalore Endocrinol & Diabet Res Ctr, Bangalore, Karnataka, India

[11] Gandhi Res Inst, Nagpur, Maharashtra, India

[12] MV Hosp & Res Ctr, Lucknow, Uttar Pradesh, India

[13] LG Life Sci, Seoul, South Korea

[14] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea

来源：

DIABETOLOGIA | 2013年 / 56卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

111

引用

页码：S52 / S52

页数：1

共 50 条

[21] Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment [J].

Nowicki, M. ;

Rychlik, I. ;

Haller, H. ;

Warren, M. L. ;

Suchower, L. ;

Gause-Nilsson, I. .

DIABETES OBESITY & METABOLISM, 2011, 13 (06) :523-532

[22] Improved glycaemic control with vildagliptin added to insulin, with or without metformin, in patients with type 2 diabetes mellitus [J].

Kothny, W. ;

Foley, J. ;

Kozlovski, P. ;

Shao, Q. ;

Gallwitz, B. ;

Lukashevich, V. .

DIABETES OBESITY & METABOLISM, 2013, 15 (03) :252-257

[23] Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone [J].

Forst, T. ;

Guthrie, R. ;

Goldenberg, R. ;

Yee, J. ;

Vijapurar, U. ;

Meiningers, G. ;

Stein, P. .

DIABETES OBESITY & METABOLISM, 2014, 16 (05) :467-477

[24] Efficacy and safety of sitagliptin or rosiglitazone when added to ongoing metformin therapy in patients with Type 2 diabetes [J].

Scott, Russell ;

Loeys, Tom ;

Davies, Michael J. ;

Engel, Samuel S. .

DIABETES RESEARCH AND CLINICAL PRACTICE, 2008, 79 :S32-S32

[25] Metformin/glyburide is safe and well tolerated as first-line therapy in patients with type 2 diabetes [J].

Davidson, J ;

Schneider, S ;

Garber, A ;

Merten, J .

DIABETES, 2000, 49 :A356-A356

[26] Sitagliptin added to ongoing treatment with pioglitazone improved glycemic control and was well tolerated in Japanese patients with type 2 diabetes (T2DM) [J].

Kashiwagi, Atsunori ;

Tajima, Naoko ;

Kadowaki, Takashi ;

Nonaka, Kenji ;

Moto, Tarooka ;

Okuyama, Kotoba ;

Nishii, Mikio ;

Stein, Peter R. .

DIABETES, 2008, 57 :A590-A590

[27] Sitagliptin added to ongoing metformin therapy enhanced glycemic control and beta-cell function in patients with type 2 diabetes [J].

Karasik, Avraham ;

Charbonnel, Bernard ;

Liu, Ji ;

Wu, Mei ;

Meehan, Alan ;

Meininger, Gary .

DIABETES, 2006, 55 :A119-A120

[28] Sitagliptin added to ongoing treatment with glimepiride improved glycemic control and was well tolerated in Japanese patients with type 2 diabetes (T2DM) [J].

Tajima, Naoko ;

Kadowaki, Takashi ;

Odawara, Masato ;

Nishii, Mikio ;

Nonaka, Kenji ;

Stein, Peter P. .

DIABETES, 2008, 57 :A589-A589

[29] Long-term (52-78 weeks) treatment with colesevelam HCl added to metformin therapy in type 2 diabetes mellitus patients [J].

Bays, Harold E. .

DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2012, 5 :125-134

[30] Luseogliflozin, a selective SGLT2 inhibitor, added on to glimepiride for 52 weeks improves glycaemic control with no major hypoglycaemia in Japanese type 2 diabetes patients [J].

Inagaki, N. ;

Seino, Y. ;

Sasaki, T. ;

Fukatsu, A. ;

Ubukata, M. ;

Umeuchi, H. ;

Sakai, S. ;

Samukawa, Y. .

DIABETOLOGIA, 2013, 56 :S82-S82

← 1 2 3 4 5 →